Why the IV-to-subcutaneous gap is not a technicality For many peptides, moving from IV to subcutaneous changes the pharmacokinetics modestly a slower rise, a lower peak, decent bioavailability
Symptoms of deficiency can vary from person to person, but may include impaired brain function, tiredness and lack of energy, breathlessness and fatigue, headaches, pale skin, heart palpitations, loss of appetite and weight loss, anxiety and depression
Still, theres promising evidence that the supplement may change the brain and nervous system in a way that helps lessen symptoms of: Major depressive disorder Schizophrenia Bipolar disorder Posttraumatic stress disorder (PTSD) Obsessive-compulsive disorder Trichotillomania (hair pulling) Substance use disorders Some studies show that the supplement may help ease symptoms of withdrawal, including a strong urge or craving to take drugs
Keeping that distinction in view prevents the most common error in this comparison: treating a standalone-monotherapy number for one and a combination number for the other as if they were measured the same way